Amonafide

Amonafide
Clinical data
Trade namesXanafide, Quinamed
ATC code
  • none
Identifiers
IUPAC name
  • 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H17N3O3
Molar mass299.330 g·mol−1
3D model (JSmol)
SMILES
  • O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI
  • InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 checkY
  • Key:UPALIKSFLSVKIS-UHFFFAOYSA-N checkY
  (verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.[1][2]

It was being developed as an anti-cancer therapy by Antisoma.[3]

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

See also

References

  1. ↑ Allen SL, Lundberg AS (July 2011). "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs. 20 (7): 995–1003. doi:10.1517/13543784.2011.585756. PMID 21591994.
  2. ↑ Freeman CL, Swords R, Giles FJ (February 2012). "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology. 5 (1): 17–26. doi:10.1586/ehm.11.68. PMID 22272701.
  3. ↑ "Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. Archived from the original on 1 April 2010.
  4. ↑ Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov

Public Domain This article incorporates public domain material from the U.S. National Cancer Institute document: "Dictionary of Cancer Terms".


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.